Newest
-
Asteroid bigger than the Leaning Tower of Pisa to pass Earth in days
-
Asteroid bigger than the Leaning Tower of Pisa to pass Earth in days
-
In response to the new civil aviation regulations, CYCJET UV laser marking machine helps power bank 3C certification logo clear and traceable
-
We could get 'proof of aliens by Christmas' after 'interstellar visitor' flies past us
DAAN Biotherapeutics Signs Antibody Exclusive Licensing Agreement with LigaChem Biosciences for ADC (Antibody-Drug Conjugate) Therapeutic Development
2025-02-14
IDOPRESS
SEOUL,South Korea,Feb. 13,2025 -- DAAN Biotherapeutics,a leading innovative drug development company specializing in T-cell receptor (TCR)- based therapies,has signed an exclusive licensing agreement with LigaChem Biosciences for a novel tumor-targeting antibody to advance the development and commercialization of Antibody-Drug Conjugates (ADC).
By leveraging DAAN Biotherapeutics' next-generation antibody technology,built upon its exceptional target discovery and antibody development capabilities,LigaChem Biosciences is now positioned to take a significant step forward in ADC development for solid tumor patients.
DAAN Biotherapeutics has successfully established a proprietary pipeline for efficiently developing antibodies targeting overexpressed tumor targets in solid cancers through a strategic partnership with OmniAb.
Byoung Chul Cho,MD,the CEO of DAAN Biotherapeutics,stated,"We will continue to develop state-of-the-art antibodies targeting solid tumors and collaborate with global pharmaceutical companies in the ADC field. Beyond ADCs,we also aim to become a global leader in solid tumor-targeting T-cell engagers using our proprietary TACTIC (Tumor Targeting Conditionally Activated T Cell Engager) platform."